The tumor-inhibiting efficacy of the compound was indeed restricted to models expressing both high PDGFB as well as high stromal PDGFRβ levels, highlighting the importance of improved knowledge on active tumoral PDGF signaling for future clinical applications. This evidence concerns the gene PDGFRB and neoplasm.